Share on StockTwits

Gilead Sciences (NASDAQ:GILD) saw unusually large options trading on Tuesday. Traders bought 74,635 call options on the company, AmericanBankingNews.com reports. This is an increase of 124% compared to the typical daily volume of 33,319 call options.

In other Gilead Sciences news, EVP Paul Rutherford Carter unloaded 10,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $106.16, for a total transaction of $1,061,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday, August 22nd. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $105.55.

Gilead Sciences (NASDAQ:GILD) traded up 1.67% during mid-day trading on Tuesday, hitting $109.36. 15,255,427 shares of the company’s stock traded hands. Gilead Sciences has a 1-year low of $58.81 and a 1-year high of $108.77. The stock’s 50-day moving average is $95.05 and its 200-day moving average is $83.00. The company has a market cap of $165.3 billion and a P/E ratio of 24.37.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.00 EPS for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.